Bacterial toxins in musculoskeletal infections
Autor: | Michelle Ghert, Thomas W. Bauer, Bryan D. Springer, Parham Sendi, Hyonmin Choe, John L. Daiss, Kordo Saeed, Paul Stoodley, Débora C. Coraça-Huber, Thomas P. Sculco, Noreen J. Hickok, Barry D. Brause, Alex C. McLaren, Edward M. Schwarz, William V. Arnold, Antonia F. Chen, Javad Parvizi, Kohei Nishitani |
---|---|
Rok vydání: | 2020 |
Předmět: |
Staphylococcus aureus
medicine.medical_specialty Bacterial Toxins 0206 medical engineering Host factors 02 engineering and technology Infections Article 03 medical and health sciences 0302 clinical medicine Antibiotic resistance AntiInfective Drugs medicine Humans Orthopedics and Sports Medicine Musculoskeletal Diseases Intensive care medicine 030203 arthritis & rheumatology Microbial toxins Potential impact business.industry Biofilm Antimicrobial 020601 biomedical engineering Biofilms Host-Pathogen Interactions business |
Zdroj: | J Orthop Res |
ISSN: | 1554-527X 0736-0266 |
Popis: | Musculoskeletal infections (MSKIs) remain a major health burden in orthopaedics. Bacterial toxins are foundational to pathogenesis in MSKI, but poorly understood by the community of providers that care for patients with MSKI, inducing an international group of microbiologists, infectious diseases specialists, orthopaedic surgeons and biofilm scientists to review the literature in this field to identify key topics and compile the current knowledge on the role of toxins in MSKI, with the goal of illuminating potential impact on biofilm formation and dispersal as well as therapeutic strategies. The group concluded that further research is needed to maximize our understanding of the effect of toxins on MSKIs, including: (i) further research to identify the roles of bacterial toxins in MSKIs, (ii) establish the understanding of the importance of environmental and host factors and in vivo expression of toxins throughout the course of an infection, (iii) establish the principles of drug-ability of anti-toxins as antimicrobial agents in MSKIs, (iv) have well-defined metrics of success for anti-toxins as anti-infective drugs, (v) design a cocktail of anti-toxins against specific pathogens to (a) inhibit biofilm formation and (b) inhibit toxin release. The applicability of anti-toxins as potential antimicrobials in the era of rising antibiotic resistance could meet the needs of day-to-day clinicians. |
Databáze: | OpenAIRE |
Externí odkaz: |